# OnCo record c4-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/c4-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "c4-therapeutics" ;
  schema:name "C4 Therapeutics"@en ;
  schema:description "Degrader company whose IKZF1/3 molecular glue cemsidomide showed a 53% response rate in heavily pretreated myeloma and entered phase 2 in 2026."@en ;
  schema:url <https://onco.cc/companies/c4-therapeutics/>, <https://c4therapeutics.com> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:citation <https://www.globenewswire.com/news-release/2026/06/11/3310320/0/en/C4-Therapeutics-Presents-Phase-1-Data-at-European-Hematology-Association-EHA-2026-Congress-Highlighting-Cemsidomide-as-a-Potential-Best-in-Class-IKZF1-3-Degrader-for-Multiple-Myelo.html> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/> ;
  onco:trials <https://onco.cc/trials/nct07284758/> .